SALT LAKE CITY, Sept. 03, 2026 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) today announced that management will present at the 2026 Cantor Global Healthcare Conference and at the H.C. Wainwright 28th Annual Global Investment Conference and host 1×1 investor meetings at both conferences.
2026 Cantor Global Healthcare Conference
Date: September 9, 2026
Time of Presentation: 9:10am ET
Location: New York, NY
Format: Presentation and 1×1 meetings
1×1 Meetings: Please contact your Cantor representative
Webcast: link to webcast
HC Wainwright 28th Annual Global Investment Conference
Date: September 15th, 2026
Time of Presentation: 1:30pm ET
Location: New York, NY
Format: Presentation and 1×1 meetings
1×1 Meetings: Please contact your H.C. Wainwright representative
Webcast: link to webcast
A webcast of the presentation will be available on the “Events” section of the Clene website or using the webcast links above.
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
Investor Contact: Kevin Gardner, LifeSci Advisors; kgardner@lifesciadvisors.com; 617-283-2856
Media Contact: Caroline Wagner, FTP; CWagner@ftpadvocacy.com; (267) 294-6563
